What is NDC 50242-007?

50242-007 is the product NDC for Enspryng (satralizumab), Satralizumab 120 mg/mL injection, solution, listed with the FDA by Genentech, Inc.. It has 4 package NDCs, shown above in 10- and 11-digit form.

Genentech, Inc., NDC labeler code 50242. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Enspryng?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Enspryng NDC 50242-007 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)50242-007Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50242-0007Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
50242-007-01	50242000701	1 SYRINGE, PLASTIC in 1 CARTON (50242-007-01) / 1 mL in 1 SYRINGE, PLASTICMarketed from Aug 14, 2020
50242-007-33	50242000733	1 SYRINGE in 1 CARTON (50242-007-33) / 1 mL in 1 SYRINGEMarketed from Jun 10, 2026 · Sample package
50242-007-55	50242000755	1 SYRINGE, PLASTIC in 1 CARTON (50242-007-55) / 1 mL in 1 SYRINGE, PLASTICMarketed from Jun 10, 2026
50242-007-86	50242000786	1 SYRINGE, PLASTIC in 1 CARTON (50242-007-86) / 1 mL in 1 SYRINGE, PLASTICMarketed from Aug 13, 2021 · Sample package

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Enspryng
Generic name (nonproprietary): satralizumab
Active ingredients: Satralizumab — 120 mg/mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: Genentech, Inc.NDC labeler code 50242
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761149
Marketing start: Aug 14, 2020
Listing expires: Dec 31, 2027
Identifiers: Product ID 50242-007_488188fd-2edc-44e0-a537-c2bd408caaa2SPL ID 488188fd-2edc-44e0-a537-c2bd408caaa2SPL set ID 64c156a4-9bad-4d45-a294-0733c141f47bRxCUI 2391555, 2391560UNII YB18NF020M

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N450242000701 followed by a unit qualifier and the quantity

Package 50242-0007-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 22, 2026.

Indications (excerpt from the label)

ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ENSPRYNG is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 50242-007

What is NDC 50242-007?: 50242-007 is the product NDC for Enspryng (satralizumab), Satralizumab 120 mg/mL injection, solution, listed with the FDA by Genentech, Inc.. It has 4 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Enspryng (Satralizumab).
What is the active ingredient?: Satralizumab.
Who is the labeler?: Genentech, Inc., NDC labeler code 50242. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Enspryng?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Enspryng (Satralizumab) NDC 50242-007